Edwards Lifesciences Corp.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US28176E1082
USD
85.78
1.8 (2.14%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Edwards Lifesciences Corp. stock-summary
stock-summary
Edwards Lifesciences Corp.
Pharmaceuticals & Biotechnology
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.
Company Coordinates stock-summary
Company Details
1 Edwards Way , IRVINE CA : 92614-5688
stock-summary
Tel: 1 949 2502500
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 183 Schemes (35.81%)

Foreign Institutions

Held by 502 Foreign Institutions (32.22%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Michael Mussallem
Chairman of the Board, Chief Executive Officer
Ms. Martha Marsh
Lead Independent Director
Mr. Paul LaViolette
Director
Ms. Ramona Sequeira
Director
Mr. Kieran Gallahue
Independent Director
Dr. William Link
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,532 Million
(Quarterly Results - Jun 2025)
Net Profit:
336 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 48,455 Million (Mid Cap)

stock-summary
P/E

30.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.33

stock-summary
Return on Equity

14.74%

stock-summary
Price to Book

4.59